Key Highlights:
- Cardio Diagnostics Holdings entered a strategic partnership with Aimil Ltd. and Dr Lal PathLabs to introduce its AI-driven blood test PrecisionCHD in India.
- PrecisionCHD detects coronary heart disease at the molecular level by combining epigenetics, genetics, and AI technology, enabling detection of both obstructive and non-obstructive disease such as INOCA and MINOCA, with supporting data presented at the American Heart Association Scientific Sessions.
- The first phase will integrate the test across Dr Lal PathLabs network of 290+ laboratories and 300+ MD pathologists, with a broader commercial rollout expected in 2026 to support earlier detection and personalized management of coronary heart disease in India.
Implications:
PrecisionCHD taps India’s $1.5B+ cardiac diagnostics market (15% CAGR), challenging ECG/stress tests via molecular insights and Dr Lal’s network for 10-15% early-detection share.
AI-epigenetics differentiation pressures traditional cardiology workflows, spurring interest in precision CV platforms as urban CHD surges 20%+ by 2030.
Success positions India as AI-cardiac screening hub, exporting to Saudi/Gulf markets with similar CVD epidemics and aging demographics.
Source: Businesswire
